Agenda
Friday, October 8, 2010 | |
7:00 a.m. | Registration |
8:15 | Keynote Lecture |
| A Systems Approach to Marker Guided Therapy in Breast Cancer |
| Joe W. Gray, PhD |
Session I: Genomics, Proteomics and Imaging | |
Session Co-chairs: Stanley R. Hamilton, MD; Lajos Pusztai, MD, PhD | |
9:15 | Introduction |
| Session Co-chairs |
9:20 | Developmental and Therapeutic Implications of the Molecular Portraits of Breast Cancer |
| Charles Perou, PhD |
9:50 | Break |
10:10 | Developing Personalized Medicine for Lung Cancer |
| John D. Minna, MD |
10:40 | Development of Clinical Proteomic and Nano Technologies For Personalized Therapy and Disease Detection |
| Emanuel (Chip) Petricoin, III, PhD |
11:10 | Matching Patients with Targeted Drugs in the Phase I Clinical Trials Setting: The Predict Program |
| Razelle Kurzrock, MD |
11:45 | Forensic Bioinformatics and Reproductibility in High-Throughput Biology |
| Keith A. Baggerly, MD The University of Texas MD Anderson Cancer Center Houston, Texas | |
| 12:15 | Lunch/Poster Session I |
Session II: Risk Models And Prevention | |
Session Co-chairs: Ernest Hawk, MD; Xifeng Wu, MD, PhD | |
1:15 p.m. | Introduction |
| Session Co-chairs |
1:20 | Clinical Acceptance of Chemoprevention of Cancer: Will It Ever Happen? |
| Michael Sporn, MD |
1:50 | The Value of SNPs for Breast Cancer Prevention |
| Mitchell H. Gail, MD, PhD |
2:20 | Defining Individual Benefit and Risk for the Treatment of Cancer Risk Factors |
| Eugene W. Gerner, PhD |
2:50 | Break |
Session III: Preclinical Models | |
Session Chair: David J. McConkey, PhD | |
3:20 | Introduction |
| David J. McConkey, PhD |
3:25 | New Concepts in Drug Discovery and Personalized Medicine |
| Dan Theodorescu, MD, PhD |
3:55 | EMT and Personalized Medicine |
| David J. McConkey, PhD |
| 4:25 | The Ernest W. Bertner Memorial Award |
| Introduction: John Mendelsohn, MD | |
| Causes and Consequences of MicroRNA Dysregulation In Cancer | |
| Carlo Croce, MD Ohio State University, Comprehensive Cancer Center Columbus, Ohio | |
Saturday, October 9, 2010 | |
9:00 a.m. | Keynote Lecture |
| Personalized Targeted Therapy and Prevention in Lung Cancer |
| Waun Ki Hong, MD |
Session IV: Personal Targeted Therapy | |
Session Co-chairs: Roy S. Herbst, MD, PhD; Elizabeth A. Grimm, PhD | |
10:00 | Introduction |
| Session Co-chairs |
10:05 | Personalized Cancer Therapy and Prevention |
| Daniel F. Hayes, MD |
10:35 | Targeting the Hedgehog Pathway in Cancer: From Bench to Bedside |
| Robert Yauch, PhD |
11:05 | Break |
Session V: Challenges To Translation | |
Session Co-chairs: John N. Weinstein, MD, PhD; Funda Meric-Bernstam, MD | |
11:30 | Introduction |
| Session Co-chairs |
11:35 | OIVD Outlook: Genetic Testing and Personalized Medicine |
| Reena Philip, PhD |
12:05 p.m. | Statistical Challenges in the Development of Reliable and Clinically Meaningful Biomarkers |
| Lisa M. McShane, PhD |
12:35 | Using Biomarkers Prospectively in Adaptive Clinical Trials to Learn Who Benefits From What |
| Donald Berry, PhD |
1:05 | Lunch/Poster Session II |
2:00 | Wilson Stone Award Presentation and Lecture |
| Introduction: Oliver Bogler, PhD |
| Emerging Challenges for Personalized Cancer Therapy: Insights from Studies of the PI3K-AKT Pathway | |
| Michael Davies, MD, PhD Assistant Professor, Melanoma Medical Oncology and Systems Biology University of Texas M. D. Anderson Cancer Center | |
2:45 | Heath Memorial Award and Lecture |
| Introduction: John Mendelsohn, MD |
| Systems Medicine and Emerging Technologies: From Reactive to Proactive (P4) Medicine |
| Leroy Hood, MD, PhD |
4:00 | Closing Remarks |
| Symposium Chairs |
4:10 | Adjourn |
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships
with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of
pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by
illness, scheduling conflicts, and so forth.
Photographing, audiotaping and videotaping are prohibited.